Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients

Obstructive Sleep Apnea Clinical Trial

— Project Dahlia  

Official title:

Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03851094
• Other study ID #: SLP-18-08-01
• Status: Completed
• Phase: N/A
• Start date: March 11, 2019
• Est. completion date: August 16, 2020

Study information

• Verified date: May 2021
• Source: ResMed
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to PAP therapy.

Description:

This is a prospective, randomized, two-arm, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to therapy. Randomization will include an allocation ratio of 2:1 (control:treatment).

Participants will be recruited based on evidence that they are struggling to achieve adherence to therapy after the first 3 nights of usage. Two 'site to participant' contacts are required during this study. These contacts can either occur at the clinical site or remotely (e.g., by telephone). During the initial contact, their interest in the study and eligibility will be confirmed, then they will be consented, asked to complete the Baseline Questionnaire, and their demographic information will be collected on case report forms (CRFs).

Participants randomized to the intervention (Group B) will be provided with information and assistance in downloading Restful to their smartphone and registering with Wellth.

At the final contact (90 days), the participant will be asked to complete an End of Study Questionnaire and the investigative staff will collect PAP therapy data for the trial period and record it on CRFs. Participants in Group B will have access to the Restful app discontinued. This completes the participant's active participation in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 166
• Est. completion date: August 16, 2020
• Est. primary completion date: May 18, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult participants (= 18 years of age)

• New diagnosis of OSA

• Prescribed CPAP or APAP for treatment of OSA

• Prescribed a ResMed flow generator compatible with AirView

• Owns a smart phone and is willing to download an app on their phone

• Willing and able to give informed consent

• Can read and comprehend written and spoken English

Exclusion Criteria:

• Have used PAP therapy in the past

• Have been prescribed bi-level or adaptive servo-ventilation therapy

• Are participating in another app-based research study

• Cannot participate for the full duration of the study (at least 90 days)

• Participants who have a medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this study, or constitutes an unacceptable risk to the participant for the duration of the study

Related Conditions & MeSH terms

• Obstructive Sleep Apnea
• Sleep Apnea, Obstructive

Intervention

Behavioral:
• Wellth app
The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.

Locations

Country	Name	City	State
United States	Sleep Data	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
ResMed	Wellth Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean PAP Usage at 90 Days	Average nightly CPAP use for the 90 day time frame.	90 days
Secondary	% of Participants That Meet Medicare Compliance Standard	Medicare compliance standard is using the PAP therapy for at least 4 hours per day on at least 70% of the days in a consecutive 30-day period any time in the first 90 days of therapy. Those that meet this standard are counted in the results below and divided by all patients.	90 days
Secondary	Change in ESS Questionnaire Scores	Epworth Sleepiness Scale (ESS) will be administered at baseline and 90 days. The unit for this outcome is points. The total score can range from 0 to 24. A larger change or change that decreases from baseline will represent a better outcome. A smaller change or change that increases from baseline will represent a worse outcome. A higher score indicates worse symptoms.	90 days
Secondary	Change in FOSQ-10 Questionnaire Scores	Functional Outcomes of Sleep Questionnaire (FOSQ-10) will be administered at baseline and 90 days. The unit for this outcome is points. The range of scores is 5 to 20. Higher scores indicate better functional status. A larger change or change that decreases from baseline will represent a better outcome. A smaller change or change that increases from baseline will represent a worse outcome.	90 days